人类免疫缺陷病毒感染个体中依非韦伦400毫克每日一次与异烟肼和利福平合用的药代动力学
研究纳入26例病毒载量<50拷贝/毫升的HIV感染者,从替诺福韦/恩曲他滨/依非韦伦600毫克转换为含依非韦伦400毫克的方案,评估合用异烟肼/利福平4周和12周后的药代动力学。合用后依非韦伦400毫克药时曲线下面积变化有限(<25%),浓度维持在ENCORE-1研究测定的范围内,无论CYP2B6基因型如何。作者认为依非韦伦400毫克可与抗结核治疗合用,该结论正在结核病患者中验证。
要点
- 26例HIV感染者改用依非韦伦400毫克后合用异烟肼/利福平,4周时药时曲线下面积几何均值比为0.91(90%CI 0.79-1.05)。
- 合用12周时依非韦伦400毫克谷浓度几何均值比较基线为0.75(90%CI 0.62-0.92)。
- 22例完成4周药代动力学者中11例携带与依非韦伦慢代谢相关的CYP2B6基因多态性。
核心结论
- 异烟肼/利福平合用与依非韦伦400毫克药时曲线下面积变化有限(<25%)相关,浓度维持在ENCORE-1研究测定的HIV感染者范围内,无论CYP2B6基因型如何。
- 作者认为依非韦伦400毫克可与抗结核治疗合用,该结论正在结核病患者中验证。
研究设计与样本
- 研究纳入26例接受替诺福韦/恩曲他滨/依非韦伦600毫克且病毒载量<50拷贝/毫升的HIV感染者,转换为替诺福韦/恩曲他滨/依非韦伦400毫克。
- 评估依非韦伦400毫克未合用(PK1)及合用异烟肼/利福平4周(PK2)和12周(PK3)后的药代动力学参数和基因多态性。
- 22例完成PK2。
主要发现
- PK2/PK1的依非韦伦400毫克峰浓度、药时曲线下面积和给药后24小时浓度几何均值比分别为0.91(90%CI 0.83-0.99)、0.91(90%CI 0.79-1.05)和0.85(90%CI 0.72-0.99)。
- PK3/PK2的峰浓度、药时曲线下面积和给药后24小时浓度几何均值比分别为0.95(90%CI 0.86-1.05)、0.88(90%CI 0.75-1.03)和0.84(90%CI 0.72-0.99)。
- PK3/PK1的峰浓度、药时曲线下面积和给药后24小时浓度几何均值比分别为0.92(90%CI 0.83-1.01)、0.84(90%CI 0.75-0.93)和0.75(90%CI 0.62-0.92)。
- 所有参与者研究期间维持病毒载量<50拷贝/毫升。
- 22例参与者中11例携带与依非韦伦慢代谢相关的CYP2B6基因多态性。
临床怎么用
- 作者认为依非韦伦400毫克可与抗结核治疗合用,该结论正在结核病患者中验证。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The World Health Organization recommends efavirenz 400 mg (EFV400) as first-line antiretroviral therapy, with a disclaimer that no data with anti-tuberculosis (TB) treatment exist. Many people living with human immunodeficiency virus (PLWH) require TB treatment with isoniazid (INH) and rifampicin (RIF), which affect cytochrome P450 and antiretroviral exposure. METHODS: PLWH receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/EFV 600 mg with a viral load (VL) <50 copies/mL switched to TDF/FTC/EFV400. Genetic polymorphisms and pharmacokinetic (PK) parameters of EFV400 without (PK1) and with INH/RIF following 4 (PK2) and 12 (PK3) weeks of coadministration were evaluated. RESULTS: Twenty-six PLWH were enrolled; 22 completed PK2. All maintained VL <50 copies/mL throughout the study. Geometric mean ratio (GMR) PK2/PK1 of EFV400 maximum plasma concentration (Cmax), area under the curve (AUC), and concentration at 24 hours postdose (C24h) were 0.91 (90% confidence interval [CI], .83-.99), 0.91 (90% CI, .79-1.05), and 0.85 (90% CI, .72-.99), respectively. GMRs (90% CI) of PK3/PK2 and PK3/PK1 Cmax, AUC, and C24h were 0.95 (.86-1.05) and 0.92 (.83-1.01), 0.88 (.75-1.03) and 0.84 (.75-.93), and 0.84 (.72-.99) and 0.75 (.62-.92), respectively. Eleven of 22 participants carried polymorphisms in the CYP2B6 gene associated with slow EFV metabolism. CONCLUSIONS: INH/RIF coadministration was associated with limited changes in EFV400 AUC (<25%), and EFV400 concentrations were maintained within ranges of those measured in PLWH in the ENCORE-1 study, irrespective of CYP2B6 genotype. The coadministration of EFV400 with anti-TB treatment can be considered and this is being confirmed in PLWH with TB. CLINICAL TRIALS REGISTRATION: NCT02832778.
引用
- Cerrone M, Wang X, Neary M, et al. Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. Clin Infect Dis. 2019. PMID: 30084943. doi:10.1093/cid/ciy491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。